There are not too many drugs that improve overall survival in prostate cancer.  Right now, the list is pretty short: Taxotere.

So the announcement that researchers have survival improvement with a new drug, cabazitaxel, is pretty exciting for us oncologists.

It's easy to become discouraged, but once in a while we get something to be happy about.  Today is one of those moments.